Santhera’s idebenone not efficient...Swiss Santhera Pharmaceuticals EU-approved LHON treatment Raxone (idebenone) has failed to show clinical efficacy in another indication: After US and EU regulators rejected an extension of market approval … more ➔
Inhaled IL-4 halts neuron destruction in... An US-German team has found a way to halt the inflammatory brain cell destruction in mice with multiple sclerosis (MS) without suppression of the human immune system. more ➔
Convert Pharmaceuticals SA closes €13.6m... Liège-based Convert Pharmaceuticals SA has been granted a total of €13.6m in equity and non-dilutive funding by investors Droia Oncology Ventures, Meusinvest and Spinventure, with non-dilutive … more ➔
Novo Holdings launches €135m fund to com...Novo Holdings has launched the REPAIR impact fund commissioned by the Novo Nordisk Foundation. The goal is to invest into early-stage drug developers with new concepts to fight antimicrobial … more ➔
Bavarian Nordic and AZ combine cancer ja... AstraZeneca (AZ) and Bavarian Nordic (BN) combine BN’s cancer vaccine CV301 and AZ’s PD-L1 checkpoint blocker durvalumab in an investigator-sponsored trail to check synergistic effects in patients with … more ➔
EMA recommends two orphan drugs for appr...The European Medicines Agency’s (EMA) Committee for Medicinal Products for Human Use (CHMP) recommended three medicines, two thereof orphan drugs, at its February 2018 meeting. more ➔
Bioeconomy: Bringing in the publicEverybody wants green production. Bioeconomy progress, however, must become more visible to consumers and let the civil society get involved to ensure socially robust innovation and perception, according … more ➔
New Screening method for Antibiotic Disc... A new method that determines the mode of action underlying antimicrobial compounds could help overcome a major stumbling block in the ongoing effort to discover new antibiotics. Using it, reseachers … more ➔
Cullinan Oncology partners with MAB Disc...Virtual oncology company Cullinan Oncology, LLC has selecteed monoclonal antibody provider MAB Discovery GmbH (Neuried) to develop the first candidate of a target portfolio of 8-10 novel … more ➔
Locking malaria parasites into red bloo...UK researchers headed by Michael Blackman have found out that a proteolytic cascade regulates release of merozoites of the human malaria parasite Plasmodium falciparum from host red blood cells. … more ➔
